Since the identification of narrow therapeutic index associated with anticoagulants and antiarrhythmic drugs, Cardiologists and Cardiovascular Physicians have searched for information on genetic risk prior to prescribing medications for their patients.
Scientific evidence reveals that responses to anti-arrhythmics, anti-hypertensives and anti-hypercholesterolemic drugs varies among the patient population.
At CQuentia, we understand patient safety is top priority. To help overcome trial and error in prescribing medications for patients with cardiovascular disorders, we have developed a comprehensive, industry-leading pharmacogenomic (PGx) test that covers 43 genes and its 209 variants, developed incorporating the guidelines laid by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in our CLIA-certified laboratory, to provide recommendations for cardiovascular diseases. Employing our PGx testing, integrated within your EMR, will ensure that actionable information is obtained at the point-of-care to personalize medication regimen and lower patient risk. Patients who’ve undergone PGx testing prior to surgery have been reported to spend 2 to 3 fewer days in post-operative care and have reported improved satisfaction in the delivery of care.
Find out what other leading institutions are saying about CQuentia.
Contact us to know about our Cardiac PGx program and whether participation in our no cost/no risk PGx program is right for your hospital or health system.
CQuentia, more than a lab, more than a test. The leaders in the new frontier of genomic testing and personalized medicine.